A single arm confirmatory study of nivolumab in patients with previously treated advanced sarcomatoid carcinoma of the lung
Phase 2
- Conditions
- advanced sarcomatoid carcinoma of the lung
- Registration Number
- JPRN-UMIN000023433
- Lead Sponsor
- ational Cancer Center Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
Not provided
Exclusion Criteria
1. Active auto-immune disease 2. Interstitial lung disease or pulmonary fibrosis 3. Active infection such as bacteria, HBV, or HCV
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Overall response rate by Central review
- Secondary Outcome Measures
Name Time Method Overall response rate by investigator, PFS, OS, DCR, Survival rate at 6 months, and toxicity